DDInter364 DDInter1269
Chlorpropamide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating β cells of the pancreas to release insulin. Sulfonylureas increase both basal insulin secretion and meal-stimulated insulin release. Medications in this class differ in their dose, rate of absorption, duration of action, route of elimination and binding site on their target pancreatic β cell receptor. Sulfonylureas also increase peripheral glucose utilization, decrease hepatic gluconeogenesis and may increase the number and sensitivity of insulin receptors. Sulfonylureas are associated with weight gain, though less so than insulin. Due to their mechanism of action, sulfonylureas may cause hypoglycemia and require consistent food intake to decrease this risk. The risk of hypoglycemia is increased in elderly, deb
Nateglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Nateglinide is an amino acid derivative that induces an early insulin response to meals decreasing postprandial blood glucose levels. It should only be taken with meals and meal-time doses should be skipped with any skipped meal. Approximately one month of therapy is required before a decrease in fasting blood glucose is seen. Meglitnides may have a neutral effect on weight or cause a slight increase in weight. The average weight gain caused by meglitinides appears to be lower than that caused by sulfonylureas and insulin and appears to occur only in those naïve to oral antidiabetic agents. Due to their mechanism of action, meglitinides may cause hypoglycemia although the risk is thought to be lower than that of sulfonylureas since their action is dependent on the presence of glucose. In addition to reducing postprandial and fasting blood glucose, meglitnides have been shown to decrease glycosylated hemoglobin (HbA1c) levels, which are reflective of the last 8-10 weeks of glucose control. Meglitinides appear to be more effective at lowering postprandial blood glucose than metformin, sulfonylureas and thiazolidinediones. Nateglinide is extensively metabolized in the liver and excreted in urine (83%) and feces (10%). The major metabolites possess less activity than the parent compound. One minor metabolite, the isoprene, has the same potency as its parent compound.
Chlorpropamide {u} (Compound) treats {v} (Disease) type 2 diabetes mellitus
type 2 diabetes mellitus {u} (Disease) is treated by {v} (Compound) Nateglinide
Chlorpropamide {u} (Compound) binds {v} (Gene) ABCC8
ABCC8 {u} (Gene) is bound by {v} (Compound) Nateglinide
Chlorpropamide {u} (Compound) causes {v} (Side Effect) Hypoglycaemia
Hypoglycaemia {u} (Side Effect) is caused by {v} (Compound) Nateglinide
Chlorpropamide {u} (Compound) resembles {v} (Compound) Probenecid
Probenecid {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nateglinide
Chlorpropamide {u} (Compound) resembles {v} (Compound) Glimepiride
Glimepiride {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nateglinide
Chlorpropamide {u} (Compound) resembles {v} (Compound) Tolbutamide
Tolbutamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nateglinide
Chlorpropamide {u} (Compound) treats {v} (Disease) type 2 diabetes mellitus
type 2 diabetes mellitus {u} (Disease) is treated by {v} (Compound) Ramipril
Ramipril {u} (Compound) resembles {v} (Compound) Nateglinide
Chlorpropamide {u} (Compound) binds {v} (Gene) ABCC8
ABCC8 {u} (Gene) is bound by {v} (Compound) Mitiglinide
Mitiglinide {u} (Compound) resembles {v} (Compound) Nateglinide
Chlorpropamide {u} (Compound) binds {v} (Gene) CYP2C9
CYP2C9 {u} (Gene) is bound by {v} (Compound) Bortezomib
Bortezomib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nateglinide
Chlorpropamide {u} (Compound) causes {v} (Side Effect) Hypoglycaemia
Hypoglycaemia {u} (Side Effect) is caused by {v} (Compound) Ramipril
Ramipril {u} (Compound) resembles {v} (Compound) Nateglinide
Chlorpropamide (Compound) treats type 2 diabetes mellitus (Disease) and type 2 diabetes mellitus (Disease) is treated by Nateglinide (Compound)
Chlorpropamide (Compound) binds ABCC8 (Gene) and ABCC8 (Gene) is bound by Nateglinide (Compound)
Chlorpropamide (Compound) causes Hypoglycaemia (Side Effect) and Hypoglycaemia (Side Effect) is caused by Nateglinide (Compound)
Chlorpropamide (Compound) resembles Probenecid (Compound) and Probenecid may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide
Chlorpropamide (Compound) resembles Glimepiride (Compound) and Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide
Chlorpropamide (Compound) resembles Tolbutamide (Compound) and Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide
Chlorpropamide (Compound) treats type 2 diabetes mellitus (Disease) and type 2 diabetes mellitus (Disease) is treated by Ramipril (Compound) and Ramipril (Compound) resembles Nateglinide (Compound)
Chlorpropamide (Compound) binds ABCC8 (Gene) and ABCC8 (Gene) is bound by Mitiglinide (Compound) and Mitiglinide (Compound) resembles Nateglinide (Compound)
Chlorpropamide (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Bortezomib (Compound) and Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide
Chlorpropamide (Compound) causes Hypoglycaemia (Side Effect) and Hypoglycaemia (Side Effect) is caused by Ramipril (Compound) and Ramipril (Compound) resembles Nateglinide (Compound)